We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-22.69%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$809M
AUM Growth
-$91.8M
Cap. Flow
+$168M
Cap. Flow %
20.82%
Top 10 Hldgs %
80.44%
Holding
30
New
6
Increased
6
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$62.2M
2
DBVT
DBV Technologies
DBVT
+$48.3M
3
ONC
BeOne Medicines Ltd
ONC
+$35.8M
4
QURE icon
uniQure
QURE
+$33.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$26.2M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$27.2M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$21.4M
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$18.4M
4
ESPR
Esperion Therapeutics
ESPR
+$8.43M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$7.45M

Sector Composition

Rank Sector Weight
1 Healthcare 96.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
26
Rigel Pharmaceuticals
RIGL
$681M
– –
-232,190
Closed -$7.45M
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-100,000
Closed -$808K
XENE icon
28
Xenon Pharmaceuticals
XENE
$6.06B
– –
-300,000
Closed -$3.96M
VIRX
29
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-60,714
Closed -$4.25M
BLPH
30
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
– –
-98,810
Closed -$1.6M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Boxer Capital held 30 positions worth $809M, down 10% from $901M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Boxer Capital deployed $168M of net new capital in Q4 2018, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 600,000 shares worth $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Medicines Co, an estimated $27.2M trimmed.

  • Boxer Capital's largest Q4 2018 buy was Intercept Pharmaceuticals, Inc.: 600,000 shares worth $60.5M.
  • Boxer Capital added most to DBV Technologies in Q4 2018, an estimated $48.3M increase.
  • Boxer Capital's biggest Q4 2018 reduction was Medicines Co, cutting an estimated $27.2M.
  • Boxer Capital fully exited Rigel Pharmaceuticals in Q4 2018, selling an estimated $7.45M.
  • Boxer Capital's ten largest holdings make up 80% of its $809M portfolio in Q4 2018.
  • Boxer Capital opened 6 new positions and closed 6 in Q4 2018.
  • Boxer Capital's portfolio value fell 10% quarter-over-quarter to $809M.

Based on Boxer Capital's 13F filing for Q4 2018, filed 14 Feb 2019.